# Pulmicort Respules(Budesonide Inhalation Suspension) vs Singulair, Children

> **NCT00641472** · PHASE4 · COMPLETED · sponsor: **AstraZeneca** · enrollment: 380 (estimated)

## Conditions studied

- Asthma

## Interventions

- **DRUG:** Budesonide inhalation suspension
- **DRUG:** Montelukast Sodium

## Key facts

- **NCT ID:** NCT00641472
- **Lead sponsor:** AstraZeneca
- **Sponsor class:** INDUSTRY
- **Phase:** PHASE4
- **Study type:** INTERVENTIONAL
- **Status:** COMPLETED
- **Start date:** 2002-10
- **Primary completion:** 2005-02
- **Final completion:** 2005-02
- **Target enrollment:** 380 (ESTIMATED)
- **Last updated:** 2009-03-25


## Primary source

ClinicalTrials.gov registry: https://clinicaltrials.gov/study/NCT00641472

## Citation

> US National Library of Medicine, ClinicalTrials.gov registration NCT00641472, "Pulmicort Respules(Budesonide Inhalation Suspension) vs Singulair, Children". Retrieved via AI Analytics 2026-06-09 from https://api.ai-analytics.org/clinical/NCT00641472. Licensed CC0.

---

*[Clinical trials dataset](/datasets/clinical-trials) · CC0 1.0*